The MOSES study was a controlled, multicentre study corresponding to the Prospective, Randomized, Open, Blinded Endpoint (PROBE) design.1
Inclusion criteria were hypertension requiring treatment, plus cerebral ischaemia/TIA/prolonged reversible ischaemic neurological deficit (PRIND) or intracerebral haemorrhage during the 24 months prior to study enrolment. All patients must have had a cerebral scan or MRI before inclusion, and ambulatory blood pressure measurements (ABPM) before randomization.
The most important exclusion criteria were stenosis of the carotid artery of >70%, severe chronic heart failure, unstable angina, valve disease, age >85 years at the time of cerebral event, and contraindications for eprosartan or nitrendipine.
